<DOC>
	<DOCNO>NCT00408551</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Internal radiation use radioactive material place directly near tumor kill tumor cell . Giving chemotherapy together internal radiation may kill tumor cell . PURPOSE : This phase II trial study well give chemotherapy together internal radiation work treat patient colorectal cancer spread liver .</brief_summary>
	<brief_title>Chemotherapy Internal Radiation Treating Patients With Colorectal Cancer That Has Spread Liver</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate tumor response , measure total tumor mass , carcinoembryonic antigen ( CEA ) level , measurable tumor volume CT scan , metabolic response positron emission tomography ( PET ) scan , patient colorectal cancer metastatic liver undergo chemotherapy selective internal radiation therapy ( SIRT ) comprise yttrium Y 90 resin microspheres . - Evaluate hepatic toxicity regimen , measure ALT , alkaline phosphatase , bilirubin level , patient . Secondary - Evaluate therapeutic efficacy regimen , use time in-liver disease progression end point , patient . - Evaluate therapeutic efficacy regimen , use down-staging resectability end point , patient . OUTLINE : This multicenter study . Patients receive 1 follow chemotherapy regimen : - FOLFOX6 : Patients receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 . Patients also receive fluorouracil IV continously 46 hour begin day 1 . - FOLFIRI : Patients receive irinotecan hydrochloride IV 1 hour leucovorin calcium IV 2 hour day 1 . Patients also receive fluorouracil IV continuously 46 hour begin day 1 . - FUDR : Patients receive floxuridine IV continuously day 1-14 . In chemotherapy regimen , treatment repeat every 2 week 8 course absence disease progression unacceptable toxicity . Patients also undergo selective internal radiation therapy ( SIRT ) comprise yttrium Y 90 resin microspheres day 2 chemotherapy course 1 ( patient receive FOLFOX6 FOLFIRI chemotherapy regimen ) day 1 , 2 , 3 , 4 , 5 course 1 ( patient receive FUDR chemotherapy regimen ) . SIRT may repeat week 10 12 . In week 18 , patient may undergo surgery down-staging occur may receive chemotherapy . After completion study therapy , patient follow every 3 month 2 year . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal cancer* meeting 1 follow criterion : Metachronous metastasis resection Dukes AC ( i.e. , stage IIII ) primary colon cancer without adjuvant chemotherapy Metachronous metastasis resection primary rectal cancer neoadjuvant adjuvant chemotherapy Synchronous metastatic liver disease symptomatic asymptomatic primary colorectal cancer NOTE : *If patient second malignancy liver metastasis potential , histologic cytologic confirmation liver lesion may perform clinically indicate Liveronly liverpredominant disease follow : Unresected primary disease Limited bone lung disease Potentially resectable nodal disease Anastomotic disease No active CNS metastasis diffuse peritoneal metastasis No hepatic metastasis second malignancy No predominant extrahepatic disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL WBC ≥ 1,500/mm^3 Creatinine ≤ 2 mg/dL Bilirubin ≤ 2 mg/dL ( without extrahepatic biliary obstruction ) Albumin &gt; 2 g/dL INR &lt; 1.5 ( without anticoagulation ) Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior externalbeam radiotherapy liver Concurrent target therapy agent ( e.g. , bevacizumab cetuximab ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>